Safety and Tolerability in Healthy Volunteers Clinical Trial
Official title:
A Phase 1, Single- and Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of NLY01 in Healthy Subjects
This is a Phase 1, first-in-human study designed to assess the safety, tolerability, and pharmacokinetics of NLY01, a PEGylated form of exenatide, in healthy volunteers. NLY01 is being developed as a potential treatment for neurodegenerative disorders including Parkinson's disease. This study is intended to identify the appropriate dose-range for evaluation in Parkinson's disease patients.
This is a Phase 1, first-in-human, double-blind, randomized, placebo-controlled, single and
multiple-dose study to assess the safety, tolerability, and PK of NLY01, a PEGylated form of
the anti-diabetic peptide exenatide, when administered by SC injection in healthy subjects.
In Part A of the study, 5 ascending-dose cohorts will be sequentially enrolled with an
evaluation of safety and tolerability prior to each dose-escalation. Subjects in each cohort
will be randomized to receive NLY01 or placebo. Each dose escalation and selection of doses
for Part B will be conducted with oversight by an independently-chaired Safety Review
Committee.
In Part B, subjects will receive once-weekly subcutaneous doses of NLY01 or placebo for 4
weeks. Three ascending-dose cohorts will be sequentially-enrolled with a safety review prior
to each dose-escalation. Subjects in all Part B cohorts will receive fixed doses of NLY01 (or
placebo) once-weekly for 4 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04535752 -
A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)
|
Phase 1 | |
Completed |
NCT04783545 -
Phase I Study of VLX-1005 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01955564 -
A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
|
Phase 1 | |
Completed |
NCT04034784 -
Discrete(TM) Safety Clinical Trial GLAD-01
|
N/A | |
Terminated |
NCT03010046 -
Single Dose Study of ANX005 in Healthy Volunteers
|
Phase 1 |